TAK - Takeda Pharmaceutical Company

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• CRISPR CMO who resigned after Casgevy approval lands at Takeda
• Jefferies’ Japan long equity list
• Protagonist Therapeutics stock rises on Takeda license deal
• Takeda Pharmaceutical gets new CFO
• Takeda Pharmaceutical GAAP EPS of ¥94.00, revenue of ¥3212.9B; reaffirms FY23 guidance
• EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze
• Takeda wins EU approval for Hyqvia CIDP indication
• New ADHD drugs could pay off for pharmaceutical companies
• Halozyme gains as U.S. and EU clear Enhanze-based products
• Drugmakers reportedly planning to raise prices on 500+ drugs in January
• FDA’s new drug approvals for 2023 rise 51% from last year
• Chinese regulators approve Takeda's post-transplant CMV treatment
• Asian markets mixed as investors remain cautious ahead of Fed decision
• JNJ multiple myeloma therapy outperforms standard of care by 58%
• Asian markets mixed as investors await U.S. inflation numbers
• Seagen lymphoma drug shows 100% progression free survival in Phase 2 trial
• Asian markets remain mixed; Japan GDP shrinks
• Asian equity markets fell, tracking Wall Street losses
• Asian markets mixed as investors look ahead to U.S. economic numbers this week
• Takeda wins FDA nod for colorectal cancer therapy